Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556006 | 0.94 | CASP2 (0.45) | CASP2PPARGPPARAHDAC3HDAC1 | |
| SCHEMBL10531381 | 0.90 | HSP90AA1 (0.55) | PPARGPPARAGMNNUSP2LMNA | |
| SCHEMBL10895511 | 0.90 | HSP90AA1 (0.55) | PPARGPPARAGMNNUSP2LMNA | |
| SCHEMBL6529676 | 0.88 | HSP90AA1 (0.52) | POLB | |
| SCHEMBL1556892 | 0.85 | PPARG (0.42) | PPARGPPARA | |
| SCHEMBL1458398 | 0.85 | HSP90AA1 (0.43) | MAPTNPSR1 | |
| SCHEMBL1556213 | 0.85 | HDAC3 (0.48) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8695869 | 0.83 | HSP90AA1 (0.52) | PPARGPPARAPOLB | |
| SCHEMBL1495189 | 0.82 | SLC6A5 (0.41) | PPARGPPARACYP1A2CYP2C19 | |
| SCHEMBL10876041 | 0.82 | HSP90AA1 (0.55) | PPARGPPARAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7285572-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135572-A1 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1630157-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASP2 1948/4885PPARG 1041/4885PPARA 921/4885 |
| US-20060135572-A1 | CaSR antagonist | CASR, CALCR, CALCRL | CASP2 2108/4885PPARG 1385/4885PPARA 1141/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASP2 1948/4885PPARG 1041/4885PPARA 921/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASP2 1948/4885PPARG 1041/4885PPARA 921/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | CASP2 2936/4885PPARG 671/4885PPARA 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.